human pro Search Results


94
R&D Systems human pro collagen i alpha 1 duoset elisa
Human Pro Collagen I Alpha 1 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pro collagen i alpha 1 duoset elisa/product/R&D Systems
Average 94 stars, based on 1 article reviews
human pro collagen i alpha 1 duoset elisa - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
MedChemExpress recombinant npy protein
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Recombinant Npy Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant npy protein/product/MedChemExpress
Average 90 stars, based on 1 article reviews
recombinant npy protein - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
R&D Systems col2a1
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Col2a1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/col2a1/product/R&D Systems
Average 93 stars, based on 1 article reviews
col2a1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech human egf protein levels
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Human Egf Protein Levels, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egf protein levels/product/Proteintech
Average 93 stars, based on 1 article reviews
human egf protein levels - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Boster Bio bbel mac387 polyclonal
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Bbel Mac387 Polyclonal, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bbel mac387 polyclonal/product/Boster Bio
Average 90 stars, based on 1 article reviews
bbel mac387 polyclonal - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Shanghai Korain Biotech Co Ltd serum ghrelin
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Serum Ghrelin, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serum ghrelin/product/Shanghai Korain Biotech Co Ltd
Average 94 stars, based on 1 article reviews
serum ghrelin - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

91
Shanghai Korain Biotech Co Ltd human egf elisa kits bioassay technology laboratory
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Human Egf Elisa Kits Bioassay Technology Laboratory, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egf elisa kits bioassay technology laboratory/product/Shanghai Korain Biotech Co Ltd
Average 91 stars, based on 1 article reviews
human egf elisa kits bioassay technology laboratory - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Boster Bio ba1503
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Ba1503, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ba1503/product/Boster Bio
Average 93 stars, based on 1 article reviews
ba1503 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Sino Biological il 18
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Il 18, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 18/product/Sino Biological
Average 90 stars, based on 1 article reviews
il 18 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Proteintech recombinant human igf ii
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Recombinant Human Igf Ii, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human igf ii/product/Proteintech
Average 93 stars, based on 1 article reviews
recombinant human igf ii - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

99
Sartorius AG incucyte s3 live cell analysis system
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Incucyte S3 Live Cell Analysis System, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/incucyte s3 live cell analysis system/product/Sartorius AG
Average 99 stars, based on 1 article reviews
incucyte s3 live cell analysis system - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

95
Chem Impex International 01523 cas
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
01523 Cas, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/01523 cas/product/Chem Impex International
Average 95 stars, based on 1 article reviews
01523 cas - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Osteocyte NPY‐induced BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of recombinant Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Advanced Science

Article Title: Neuronal Induction of Bone‐Fat Imbalance through Osteocyte Neuropeptide Y

doi: 10.1002/advs.202100808

Figure Lengend Snippet: Osteocyte NPY‐induced BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of recombinant Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: 24 h later, the culture medium was replaced with fresh osteogenic or adipogenic medium (Cyagen) supplemented with OCY‐CM (300 μg mL −1 at the protein level) from different groups, recombinant NPY protein (0.1 n m ; MedChemExpress), BIBO3304 (0.1 n m ; Selleck Chemicals, Houston, USA), NPY (0.1 n m ) + db‐cAMP (10 μ m ; MedChemExpress), NPY (0.1 n m ) + H‐89 (10 μ m ; MedChemExpress), NE (0.1 n m ; Sigma‐Aldrich), ACh (0.1 n m ; Sigma‐Aldrich), or an equal volume of vehicle.

Techniques: Inhibition, Quantitative RT-PCR, Expressing, Western Blot, Over Expression, Recombinant, Staining, Activity Assay, Enzyme-linked Immunosorbent Assay, Immunoprecipitation, Negative Control, Positive Control, Two Tailed Test, Control